|
Search Term: " Glycerylphosphorylcholine "
Can Alpha GPC Really Help With Memory And Growth ?   
Date:
September 29, 2011 11:52 AM
What Are The Benefits Of Alpha GPC? L-Alpha Glycerylphosphorylcholine, or abbreviated as Alpha GPC, is a natural compound which is choline in nature. It is considered to be an acetylcholine precursor which is now being studied as a treatment for the degenerative disease called Alzheimer’s disease. This chemical compound also has a parasympathomimetic property and is widely used as a nutritional supplement for enhancing memory and concentration. The other name of Alpha GPC is Choline Alfoscerate. Alpha GPC has the capacity to rapidly transport choline to the central nervous system by passing through the blood - brain barrier. Alpha GPC can be extracted from highly distilled soy phospholipids such as lecithin. Inside the body, this chemical compound can be found in high quantity in neuronal membranes. Some of its benefits are: 1. IMPROVES ACETYLCHOLINE LEVEL. As mentioned earlier, Alpha GPC can cross the blood – brain barrier. Once inside the brain, it positively influences brain activity by enhancing the production of acetylcholine. Acetylcholine is a neurotransmitter which is responsible for improving the individual’s learning process. Acetylcholine acts on both the peripheral and central nervous system. In the former, this neurotransmitter functions as the main neurotransmitter in the autonomic nervous system. It is also involved in the contraction of body muscles. In the latter, acetylcholine acts as an anti – excitatory chemical in the cholinergic system. 2. MEMBRANE COMPONENT. Another health benefit of Alpha GPC is that it can effectively protect nerve cells thus improving the transmission of impulse. Aside from maintaining the integrity of the nerves and nerve cells, Alpha GPC also serves as a precursor of the phospholipids found on membranes. 3. INCREASE HUMAN GROWTH HORMONE. Studies on Alpha GPC have revealed that it can relatively influence the action of the body’s Growth Hormone – Releasing Hormone (GHrH), thus improving the release of growth hormones. In addition, it can also enhance the effects of human growth hormone especially among young individuals. 4. A MODALITY FOR DEMENTIA. Alpha GPC has been long studied for the treatment of senile dementia. Initial result of such studies revealed that patients supplemented with Alpha GPC showed improvement but on a smaller extent. Further studies are still being conducted so that efficacy and safety as well as the appropriate dosage will be determined. 5. INFLUENCES GABA. Studies reveal that Alpha GPC significantly increase the synthesis and release of Gamma Amino – Butyric Acid or GABA. Increased synthesis of GABA is also potentiated by atropine. GABA is considered as the principal inhibitory brain chemical among mammals. It has a significant role in controlling neuronal excitation all over the nervous system. Like acetylcholine, GABA is also one of the primary responsible chemicals for the control of muscle tone. Alpha GPC is formulated as supplement. It is available in 300 to 1,200 milligram oral supplements. Though it is generally safe, it is important that you should consult your doctor first before using this supplement. This would significantly avoid the occurrence of adverse effects and drug interactions. Appropriate dosage will also be determined by your doctor. Remember, any medication or supplement varies from person to person on its therapeutic and adverse effects.
(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=2468) ALPHA GPC - Improves Mental Performance 
Date:
June 28, 2005 06:21 PM
The quality of our life experience—and our ability to live life to the fullest—is a direct result of optimal brain function. Only a few years ago, nothing could be done to stem the tide of poor circulation, forgetfulness and “mental fog.” But neurological science exploration has identified a fundamental brain compound critical to attention, learning, memory, and even the higher cognitive functions of reasoning and intuition. Research confirms that L-alpha-Glycerylphosphorylcholine (called Alpha-GPC for convenience) is crucial to neuronal function and structure. Derived from purified soy lecithin, Source Naturals ALPHA-GPC readily converts to acetylcholine in the brain, helping to maintain neuronal structure integrity. Source Naturals provides an easy and convenient means to profoundly impact the very nexus of our body and mind. GPC Is Unique No other nutritional compound comes close to GPC in its ability to boost critically important acetylcholine levels. Found in both the brain and the peripheral nervous system (including the nerve-muscle junctions), acetylcholine is a key nerve messenger molecule, or neurotransmitter. Aging brains are characterized by functional deficiencies in both acetylcholine and its cholinergic receptors. GPC is a highly bioavailable supplement that boosts acetylcholine levels to improve cognitive function. It is also a major choline reservoir, helping to protect the brain against damage from poor circulation and potentially toxic metabolites. Deficiencies in acetylcholine can cause the body to break down phosphatidylcholine for its choline content, leading to the death of brain cells. Yet in controlled clinical trials of middle-aged subjects taking GPC, reaction time was enhanced and there was improved energy generation and electrical coordination in the brain. For older subjects, double-blind trials demonstrated that GPC had superior benefits over certain other brain nutrients for mental focus, recall, verbal fluency—a unique, marked overall enhancement of mental performance. GPC is an example of what the great Linus Pauling referred to as “orthomolecules,” that is, molecules that are “orthodox” or “correct” for the body. GPC excels as a protective nutraceutical for memory loss and mood enhancement. It protects cells of the brain (and other organs) from damage, shielding a range of important biomolecules against toxin build-up. Extensive Clinical Testing In clinical trials that involved more than 5,000 patients, GPC showed marked improvement in overall brain performance. Depending on the particular trial, 50-70 percent of the patients who received GPC had their mental functions improved to a degree “meaningful to life quality.” GPC has shown revitalizing effects on the declining brain, and preliminary evidence suggests GPC may act on the pituitary gland to partially restore its capacity to make vital for cell maintenance and longevity. Other unique brain features of GPC are its benefits for attention and recall in young healthy adults, and its superior bioavailability. GPC readily crosses the bloodbrain barrier to raise brain choline levels within a few hours following oral intake. GPC helps with body-mind integration by being a ready reservoir for acetylcholine. This neurotransmitter is ubiquitous in brain circuit maturation, expansion, renewal and repair, as well as in the “agility” or adjustments of the circuitry that occur during adult life. In addition, an animal study has shown that GPC increases the release of GABA (gamma-aminobutyric acid), the most important and abundant inhibitory neurotransmitter in the brain. It acts as a “balancer” for the brain and helps induce relaxation and sleep. Without sufficient GABA, neurons fire at random, unable to make sense of incoming signals. GABA helps minimize “neural noise,” making it easier to focus and concentrate. Why you should take GPC:
References:
(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=514) Glycerylphosphorylcholine -- Supports Cognitive Function in AD ... 
Date:
May 24, 2005 09:52 AM
Cognitive Improvement in Mild to Moderate Alzheimer's Dementia After Treatment with the Acetylcholine Precursor Choline Alfoscerate: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Maria De Jesus Moreno Moreno, MD Instituto Nacional de la Senectud, Mexico City, Mexico
in both men and woman they consistently improved after 90 and 180 days versus baseline with adiministration of GPC three times a day, whereas in the placebo group they remained unchanged or worsened. Statistically significant differences were observed between treatments after 90 and 180 days. Keypoints: references: Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction, Science. 1982;217:408-414. 2. Larson EB, Kukull WA, Katzman RL. Cognitive impairment: Dementia and Alzheimer's disease. Annu Rev Public Health. 1992;13:431-449. 3. Hofman A, Rocca WA, Brayne C, et al, for the European Prevalence Research Group. The prevalence of dementia in Europe: A collaborative study of 1980-1990 findings. Int d Epidemiol. 1991;20:736-748. 4. Blackwood W, Corsellis JAN, eds. Greenfield's Neuropathology. 3rd ed. London: Arnold; 1976. 5. Geldmacher DS. Cost-effective recognition and diagnosis of dementia. 5emin Neurol. 2002;22:63-70. 6. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ. 1978;2:1457-1459. 7. Perry EK. The cholinergic hypothesis--ten years on. Br Med Bull. 1986;42:63-69. 8. Giacobini E. From molecular structure to Alzheimer therapy. Jpn d Pharmacol. 1997;74:225-241. 9. Giacobini E. Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications. Neurochem Int. 1998;32:413-419. 10. Brinkman SD, Smith RC, Meyer JS, et al. Lecithin and memory training in suspected Alzheimer's disease. J Gerontol. 1982;37:4-9. 11. Davis E, Emmerling MR, Jaen JC, et al. Therapeutic intervention in dementia. Crit Rev Neurobiol. 1993;7:41-83. 12. Amenta E Parnetti L, Gallai V, Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropiate approaches? Mech Ageing Dev. 2001;122:2025-2040. 13. Sigala S, Imperato A, Rizzonelli P, et al. k-Alpha-Glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. Eurd Pharmacol. 1992;211:351-358. 14. Govoni S, Battaini E Lucchi L, et al. Effects of alpha-Glycerylphosphorylcholine in counteracting drug-induced amnesia: Through cholinergic and non-cholinergic mechanisms [in Italian]. Basi Raz Ter. 1991;21:75-78. 15. Canonico PL, Nicoletti F, Scapagnini U. Neurochemical and behavioral effects of alpha-Glycerylphosphorylcholine [in Italian]. Basi Raz Te~ 1990;20: 53-54. 191 CLINICAL THERAPEUTICS ® 16. Parnetti L, Amenta E Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: An analysis of published clinical data. Mech Ageing Dev. 2001;122:2041-2055. 17. Venn RD. The Sandoz Clinical Assessment-Geriatric (SCAG) scale. A general-purpose psychogeriatric rating scale. Gerontology. 1983;29:185-198. 18. Di Perri R, Coppola G, Ambrosio LA, et al. A multicentre trial to evaluate the efficacy and tolerability of alpha-Glycerylphosphorylcholine versus cytosine diphosphocholine in patients with vascular dementia. J Int Med Res. 1991;19:330-341. 19. Frattola L, Piolti R, Bassi S, et al. Multicenter clinical comparison of the effects of choline alphoscerate and cytidine diphosphocholine in the treatment of multi-infarct dementia. Curt Ther Res Clin Exp. 1991;49:683-693. 20. Muratorio A, Bonuccelli U, Nuti A, et al. A neurotropic approach to the treatment of multi-infarct dementia using L-c~-Glycerylphosphorylcholine. Curt Ther Res Clin Exp. 1992;52:741-75l. 21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: APA; 1994. 22. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944. 23. Folstein ME Folstein SE. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198. 24. Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke. 1983;14:399-401. 25. Hamilton M. A rating scale for depression.J Neurol Neurosurg Psychiatry. 1960;23:56-62. 26. Hamilton M. Development of a rating scale for primary depressive illness. BrJ Soc Clin Psych& 1967;6:278-296. 27. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. AmJ Psychiatry. 1984;141:1356-1364. 28. Reisberg B, Ferris SH, De Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136-1139. 29. National Institute of Mental Health. Clinical global impressions. In: Guy W, ed. ECDEU Assessment for Psychopharmacology. Revised edition. Rockville, Md: National Institute of Mental Health; 1976:217-222. 30. Burns A, Russell E, Page S. New drugs for Alzheimer's disease. Br J Psychiatry. 1999;174:476-479. 31. Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol. 2000;7:159-169. 32. Knapp MJ, Knopman DS, Solomon PR, et al, for the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994;271:985-991. 192 M. Moreno 33. Lindstrom MJ, Bates DM. Newton-Rapshon algorithms for linear-mixed effects models for repeated measure data. J Am Stat Assoc. 1998;83:1014-1022. 34. Thai LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996;47:705-711. 35. Rogers SL, Friedhoff LT, for the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293-303. 36. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, for the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998; 158:1021-1031. 37. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and the safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1:55-65. 38. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ. 1999;318: 633-638. 39. Amenta E Bronzetti E, Del Valle M, Vega JA. Effects of alpha-Glycerylphosphorylcholine in neuroanatomy of aging brain in experimental animals [in Italian]. Basi Raz Te~: 1990;20:31-38. Address correspondence to: Scientific Department, Italfarmaco SpA, via dei Lavoratori 54, 20092 Cinisello Balsamo, Milan, Italy.
(https://vitanetonline.com:443/forums/Index.cfm?CFApp=1&Message_ID=98) | ||||||||||||||||||||||||
